Cosmos Health CEO Greg Siokas and CFO George Terzis Collectively Increase Stake by 343,000 Shares Valued at $200,000

Rhea-AI Summary

Cosmos Health (NASDAQ:COSM) announced that CEO Greg Siokas and CFO George Terzis have increased their stake in the company by approximately 343,122 common shares, valued at $200,000. Mr. Siokas acquired 257,334 shares worth $150,000, while Mr. Terzis purchased 85,778 shares valued at $50,000.

The CEO expressed disappointment in the current share price, which he believes is below the company's intrinsic value, but views it as an opportunity for increased investment. He highlighted the company's assets, including growing proprietary brands, a pharmaceutical GMP license for contract manufacturing, and an R&D team working on cancer and obesity treatments.

Positive

• Insider buying: CEO and CFO collectively purchased $200,000 worth of shares
• Company possesses GMP license enabling high-margin contract manufacturing services
• Maintains R&D pipeline in cancer and obesity treatments
• Operates with vertical integration in healthcare products

Negative

• Share price performing significantly below management's expected valuation
• Current profitability concerns indicated by CEO's statement about 'delivering sustained profitability'

Insights

Financial Analyst

The insider buying at Cosmos Health presents a noteworthy signal, with CEO and CFO collectively purchasing $200,000 worth of shares at current market prices. This represents a significant commitment given the company's small market cap of $14.8M. The purchase price implies the executives bought at approximately $0.58 per share, demonstrating their conviction that the stock is undervalued. Insider purchases of this magnitude, representing about 1.3% of the company's market cap, typically indicate strong management confidence in future performance. However, investors should note that while insider buying is generally a positive signal, the company's micro-cap status and current trading levels suggest significant execution risks remain. The emphasis on proprietary brands, GMP licensing and R&D pipeline developments indicates potential growth catalysts, but the path to sustained profitability remains uncertain.

Market Research Analyst

The strategic timing of these insider purchases warrants attention in the context of Cosmos Health's business transformation efforts. The company's diversification across pharmaceuticals, nutraceuticals and telehealth positions it uniquely in the healthcare sector. The emphasis on vertical integration through GMP licensing could lead to improved margins through contract manufacturing opportunities. The management's focus on proprietary brands with global reach suggests a scalable business model, while the R&D investments in high-value therapeutic areas like cancer and obesity indicate potential for significant value creation. However, the current market cap suggests investors remain skeptical about near-term execution. The insider buying, particularly at these depressed valuations, may serve as a catalyst for renewed investor interest, especially if operational improvements materialize in upcoming quarters.

CHICAGO, IL / ACCESSWIRE / December 23, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its CEO, Greg Siokas, and CFO, George Terzis, increased their stake in the Company by approximately 343,122 common shares, valued at $200,000, based on the closing share price on Friday, December 20, 2024.

Specifically, Mr. Siokas increased his stake by approximately 257,334 common shares, valued at $150,000, while Mr. Terzis increased his stake by approximately 85,778 common shares, valued at $50,000.

Greg Siokas, CEO of Cosmos Health, stated: "While I am disappointed that our share price has fallen well below what I believe reflects Cosmos's intrinsic value, I am equally encouraged by the opportunity to increase my stake at such an attractive valuation. This decision, along with our CFO's choice to boost his stake, highlights our shared confidence in the Company's future and its immense potential. Cosmos, among others, boasts exceptional assets, including fast-growing proprietary brands with global reach, a valuable pharmaceutical GMP license enabling vertical integration and high-margin contract manufacturing services (CMO), and a world-class R&D team with a robust pipeline in critical areas such as cancer and obesity. I remain dedicated to delivering sustained profitability, which I firmly believe will, in time, be reflected in our share price."

About Cosmos Health Inc.

Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, as well as LinkedIn and X.

Forward-Looking Statements

With the exception of the historical information contained in this news release, the matters described herein, may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, followed by, or that otherwise, include the words "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans" and similar expressions or future or conditional verbs such as "will," "should," "would," "may" and "could", are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements, involve unknown risks and uncertainties that may individually or materially impact the matters discussed, herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company's ability to raise sufficient financing to implement its business plan, the impact of the COVID-19 pandemic and the war in Ukraine, on the Company's business, operations and the economy in general, and the Company's ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward- looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's filings with the SEC, which are available at the SEC's website (www.sec.gov). The Company disclaims any intention or obligation to update, or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Contact:

BDG Communications
cosm@bdgcommunications.com
+44 207 0971 653

SOURCE: Cosmos Health Inc.

View the original press release on accesswire.com

FAQ

How many shares did Cosmos Health (COSM) insiders purchase in December 2024?

Cosmos Health insiders purchased 343,122 shares in December 2024, with CEO Greg Siokas buying 257,334 shares ($150,000) and CFO George Terzis acquiring 85,778 shares ($50,000).

What is the total value of the insider purchase of COSM stock in December 2024?

The total value of the insider purchase was $200,000, based on the closing share price on December 20, 2024.

What are the main business segments of Cosmos Health (COSM)?

Cosmos Health operates in pharmaceutical and nutraceutical brands, healthcare product manufacturing and distribution, innovative R&D, and telehealth platform services.

What key assets does COSM currently possess according to the CEO?

According to the CEO, COSM's key assets include fast-growing proprietary brands with global reach, a pharmaceutical GMP license for contract manufacturing, and an R&D team working on cancer and obesity treatments.